Advertisement
Canadian Journal of Cardiology

No Longer the “Forgotten Valve”? Tricuspid Regurgitation Management and Outcomes: Narrowing the Knowledge Gap One Step at a Time

  • Géraldine Ong
    Affiliations
    Division of Cardiology, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

    Kennan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada
    Search for articles by this author
  • Kim A. Connelly
    Correspondence
    Corresponding author: Dr Kim A. Connelly, Division of Cardiology, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada. Tel.: 416-864-5201.
    Affiliations
    Division of Cardiology, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

    Kennan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, Ontario, Canada
    Search for articles by this author
Published:February 01, 2021DOI:https://doi.org/10.1016/j.cjca.2021.01.022
      In recent years, there has been growing interest in the tricuspid valve (TV), and numerous studies have confirmed that severe tricuspid regurgitation (TR) is a clinically significant disease associated with adverse outcomes.
      • Shiran A.
      • Sagie A.
      Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shiran A.
        • Sagie A.
        Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management.
        J Am Coll Cardiol. 2009; 53: 401-408
        • Lurz P.
        • Stephan von Bardeleben R.
        • Weber M.
        • et al.
        Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation.
        J Am Coll Cardiol. 2021; 77: 229-239
        • Muntané-Carol G.
        • Alperi A.
        • Faroux L.
        • et al.
        Transcatheter interventions for tricuspid valve disease: what to do and who to do it on.
        Can J Cardiol. 2021; 37: 953-967
        • Fam N.P.
        • Ong G.
        • Deva D.P.
        • Peterson M.D.
        transfemoral transcatheter tricuspid valve replacement.
        JACC Cardiovasc Interv. 2020; 13: e93-e94
        • Hahn R.T.
        • Meduri C.U.
        • Davidson C.J.
        • et al.
        Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results.
        J Am Coll Cardiol. 2017; 69: 1795-1806
        • Ho E.C.
        • Ong G.
        • Fam N.P.
        Transcatheter tricuspid valve intervention: a practical algorithm for patient selection.
        Curr Opin Cardiol. 2019; 34: 164-172
        • Mehr M.
        • Taramasso M.
        • Besler C.
        • et al.
        1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry.
        JACC Cardiovasc Interv. 2019; 12: 1451-1461
        • Zack C.J.
        • Fender E.A.
        • Chandrashekar P.
        • et al.
        National trends and outcomes in isolated tricuspid valve surgery.
        J Am Coll Cardiol. 2017; 70: 2953-2960
        • Messika-Zeitoun D.
        • Candolfi P.
        • Dreyfus J.
        • et al.
        Management and outcomes of patients admitted with tricuspid regurgitation in France.
        Can J Cardiol. 2021; 37: 1078-1085
        • Cai S.
        • Bowers N.
        • Dhoot A.
        • et al.
        Natural history of severe tricuspid regurgitation: outcomes after transcatheter tricuspid valve intervention compared to medical therapy.
        Int J Cardiol. 2020; 320: 49-54
        • Nishimura R.A.
        • Otto C.M.
        • Bonow R.O.
        • et al.
        2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2438-2488
        • Faggion Vinholo T.
        • Mori M.
        • Mahmood S.U.B.
        • et al.
        Combined valve operations in the aortic and mitral positions with or without added tricuspid valve repair.
        Semin Thorac Cardiovasc Surg. 2020;
        • Desai R.R.
        • Vargas Abello L.M.
        • Klein A.L.
        • et al.
        Tricuspid regurgitation and right ventricular function after mitral valve surgery with or without concomitant tricuspid valve procedure.
        J Thorac Cardiovasc Surg. 2013; 146: 1126-1132. e1110
        • Pfannmuller B.
        • Davierwala P.
        • Hirnle G.
        • et al.
        Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery.
        Ann Cardiothorac Surg. 2013; 2: 758-764
        • Nath J.
        • Foster E.
        • Heidenreich P.A.
        Impact of tricuspid regurgitation on long-term survival.
        J Am Coll Cardiol. 2004; 43: 405-409

      Linked Article